2015-2016 Recently Appointed Professors

As of May 9th, 2016

William J. Barbaresi, M.D.

Dr. Barbaresi is Professor of Pediatrics at Boston Children’s Hospital where he is the Associate Chief of the Division of Developmental Medicine. He is a recognized leader in research on the epidemiology and long-term outcomes of attention-deficit/hyperactivity. His ongoing research is focused on interventions to improve outcomes for children with developmental disorders.

Jeffrey P. Burns, M.D., M.P.H.

Dr. Burns is Professor of Anaesthesia at Boston Children’s Hospital where he is Chief of Critical Care Medicine and Chair of the ICU Governance Committee. He is a renowned educator and has developed two innovative educational instruments that have had enormous impact on the care of critically ill children throughout the world. He has also developed a pediatric critical care transport unit to assist critically ill children and transport them to areas of specialty care and facilitated interdisciplinary collaborations with surgery, neurology and radiology to assure broad coordinated coverage for pediatric care.

Keith T. Flaherty, M.D.

Dr. Flaherty is Professor of Medicine at Massachusetts General Hospital where he is Director of the Termeer Center for Targeted Therapy and Director of Clinical Research at the MGH Cancer Center. He conducts clinical and translational research focusing on the MAP kinase signaling pathway to develop treatments for melanoma. This research has identified specific mechanisms of resistance that has led to FDA approved treatment regimens.

Stuart A. Forman, M.D., Ph.D.

Dr. Forman is Professor of Anaesthesia at Massachusetts General Hospital. He is a respected clinician scientist who is credited for exploiting existing technology and models to develop and further a new paradigm in the molecular basis of anesthesia function. His research contributions have shifting the focus of anesthetic action by showing that inhalant anesthetics do not exert their effects by interacting with the lipid membrane of neurons but rather by interacting with discrete lipophilic binding sites on different types of receptors.
Eric Garshick, M.D.

Dr. Garshick is Professor of Medicine at the VA Boston Healthcare System where he is Associate Chief of the Pulmonary, Allergy, Sleep and Critical Care Medicine Section. His research was instrumental in demonstrating that diesel exhaust exposure increased the risk of lung cancer, which provided the scientific basis for classifying diesel exhaust as a human carcinogen. He has also focused on understanding the natural history and impact of respiratory dysfunction in chronic spinal cord injury and is currently assessing its effects on pulmonary function in veterans who served in Iraq and Afghanistan.

Elizabeth S. Ginsburg, M.D.

Dr. Ginsburg is Professor of Obstetrics, Gynecology and Reproductive Biology at Brigham and Women’s Hospital where she is the Associate Director of BWH Center for Infertility and Reproductive Surgery, Medical Director of the Assisted Reproductive Technologies Program, Director of BWH-DFCI Fertility Preservation Program and Director of the Reproductive Endocrinology and Infertility Fellowship Program. Her expertise is in assisted reproductive technology, oncofertility and menopause. Some of her major areas of contribution include estradiol metabolism and alcohol ingestion increasing risk for breast cancer; development of an algorithm for selecting day and number of embryos transferred to reduce multiple pregnancies; and the impact of obesity on in vitro fertilization outcomes.

Michael M. Givertz, M.D.

Dr. Givertz is Professor of Medicine at Brigham and Women’s Hospital where he is Medical Director of the Heart Transplant and Mechanical Circulatory Support Program. His major research achievements have focused on cardiorenal syndrome and novel therapies for advanced heart disease. He is currently a principal investigator in the NHLBI Heart Failure Network.

Richard I. Gregory, Ph.D.

Dr. Gregory is Professor of Biological Chemistry and Molecular Pharmacology at Boston Children’s Hospital. His research is focused on understanding the molecular mechanisms controlling microRNA biogenesis in stem cells which has opened up new avenues of research in stem cell biology, development, regeneration, cancer and glucose metabolism. This has led to research aimed at manipulating these pathways as a new therapeutic approach for cancer and degenerative diseases.
Jeffrey R. Holt, Ph.D.

Dr. Holt is Professor of Otolaryngology at Boston Children’s Hospital where he is the Director of Otolaryngology Research. His work focuses on the function and dysfunction of the sensory receptors in the inner ear. His team has discovered several proteins that are at the core of the sensory transduction process that converts sound information into electrical signals; they are working on translating these discoveries into novel therapies for treatment of genetic hearing loss.

A. John Iafrate, M.D., Ph.D.

Dr. Iafrate is a Professor of Pathology at Mass General Hospital where he is the Director of the Center for Integrated Diagnostics. He has developed diagnostics for personalized genomic testing to help inform cancer treatment decisions for patients. His research is focused on lung and brain tumors, where he has been closely involved in the clinical development of crizotinib and companion diagnostics in ALK- and ROS1-positive lung cancers.

James D. Kang, M.D.

Dr. Kang is Professor and Head of the Department of Orthopedic Surgery at Brigham and Women’s Hospital. He is a clinician-scientist with expertise in spinal disorders whose work is focused on the mechanisms of intervertebral disc degeneration and developing novel molecular and biological therapies. He is also a leader in the field of orthopedic spinal surgery and is recognized for his clinical outcomes research.

Elizabeth W. Karlson, M.D.

Dr. Karlson is Professor of Medicine at Brigham and Women’s Hospital where she is Director of Rheumatic Disease Epidemiology in the Section of Clinical Sciences, Division of Rheumatology, Allergy and Immunology. She is a leader in prediction modeling of rheumatic disease outcomes and bioinformatics analysis of electronic health records for clinical and translational research. Her work has made major contributions to understanding environmental and genetic and interactions in rheumatic disease and to advancing genotype-phenotype analyses for precision medicine.
Harry P.W. Kozakewich, M.D.

Dr. Kozakewich is Professor of Pathology at Boston Children’s Hospital where he is the Director of the Autopsy Service. His work has primarily been on the pathology of pediatric pulmonary and oncologic disorders. He is currently focused on identifying vascular malformations and tumors including seminal descriptions of novel pediatric vascular lesions.

Jordan A. Kreidberg, M.D., Ph.D.

Dr. Kreidberg is Professor of Pediatrics at Boston Children’s Hospital where he founded and directs the Office of Fellowship Training. He is also a member of the Executive Committee of the HMS Pathways Committee on Admissions. His research is also focused on the developmental biology of the kidney, specifically on Polycystic Kidney Disease and Glomerular Disease.

Glenn M. LaMuraglia, M.D.

Dr. LaMuraglia is Professor of Surgery at the Mass General Hospital. He is a recognized leader in carotid surgery and revascularization paradigms of the lower extremity. He also investigates novel photobiology approaches to inhibit vascular restenosis.

Edward Anthony Nardell, M.D.

Dr. Nardell is Professor of Medicine at Brigham & Women’s Hospital in both the Divisions of Global Health Equity and Pulmonary and Critical Care Medicine. He focuses on tuberculosis transmission and has developed a sustainable germicidal ultraviolet air disinfection to control airborne infection. His most recent research findings on the almost immediate impact of active case finding, rapid molecular diagnosis, and effective treatment on TB transmission have led to refocused administrative approaches to hospital infection control internationally.
Samuel Nurko, M.D.

Dr. Nurko is Professor of Pediatrics at Boston Children’s Hospital where he is the Director of the Center for Motility and Functional Gastrointestinal Disorders. He has made major contributions to the understanding of motility and functional GI disorders in children. His clinical and research interests have focused on understanding the pathophysiology and establishing the best approach and treatments for these disorders in the pediatric population.

Emily Oken, M.D., M.P.H.

Dr. Oken is Professor of Population Medicine at the Harvard Pilgrim Health Care Institute where she is Director of Faculty Development and she serves as an Associate Director and Advisor in the Oliver Wendell Holmes Society at HMS. Dr. Oken’s research focuses on the influence of nutrition and other modifiable factors during pregnancy and early childhood on long-term maternal and child health. Her work on the toxicant risks and nutrient benefits of prenatal fish consumption has influenced national guidelines for fish consumption during pregnancy.

Aria F. Olumi, M.D.

Dr. Olumi is Professor of Surgery at Mass General Hospital where he is the Residency Program Director in Urologic Surgery. His research on benign prostatic hyperplasia, the most common worldwide neoplastic disease, examines the varying growth rates of human adult prostate tissue, a process that is regulated by epigenetic modifications. In addition, he creates initiatives to better educate and increase the workforce of physician scientists.

C. Keith Ozaki, M.D.

Dr. Ozaki is Professor of Surgery at the Brigham and Women’s Hospital where he is Director of Vascular Surgery Research at the Carl J. and Ruth Shapiro Cardiovascular Center. He has led basic vascular research efforts that broadly aim to delineate how physical forces alter the morphology of the blood vessel wall. Recent investigations have focused on inflammatory and adipose driven mechanisms of these adaptations, and interventions such as dietary restriction.
Dennis S. Poe, M.D., Ph.D.

Dr. Poe is Professor of Otolaryngology at Boston Children’s Hospital. He investigates the diagnosis and management of disorders of the Eustachian tube in children and adults and has developed diagnostic methods, novel medical treatments, new surgical procedures and instruments. He is the principal investigator for an ongoing national, multicenter, randomized, controlled, clinical trial of balloon dilation of the Eustachian tube.

Mustafa Sahin, M.D., Ph.D.

Dr. Sahin is Professor of Neurology at Boston Children’s Hospital where he is the Director of the Translational Neuroscience Center. Work in his lab has identified the mechanisms by which tuberous sclerosis, a genetic disease, leads to miswiring of neurons in the brain. Current research focuses on translating these preclinical findings into the clinic and developing.

Robert L. Sheridan, M.D.

Dr. Sheridan is Professor of Surgery at Mass General Hospital and is the medical director of the burn program at Boston Shriners Hospital for Children. He is a recognized leader in the longitudinal care of burn patients. His research focuses on tracking and optimizing long-term physical and emotional outcomes after burns, particularly children.

Scott A. Shikora, M.D.

Dr. Shikora is Professor of Surgery at Brigham and Women’s Hospital where he is the Director of the Center for Metabolic and Bariatric Surgery. He was involved with the early development and testing of bariatric surgical methods which has led to modifications in the standard of care and initial testing of a novel non-surgical approach to weight loss and improvements of metabolic syndrome. He is also an expert on surgical nutrition support.
Jonathan P. Winickoff, M.D., M.P.H.

Dr. Winickoff is Professor of Pediatrics at Massachusetts General Hospital. He is a Practicing General Pediatrician and Director of Translational Research for the American Academy of Pediatrics Julius B. Richmond Center of Excellence. His research and advocacy have started local and national movements to make public housing smoke free, raise the tobacco sales age to 21, and help parents quit smoking in the context of pediatric healthcare.

Peng Yin, Ph.D.

Dr. Yin is Professor of Systems Biology at Harvard Medical School and a Core Faculty Member at the Wyss Institute for Biologically Inspired Engineering. He is an expert in synthetic biology, DNA/RNA based nanotechnology and molecular programming. Work in his lab focuses on engineering synthetic DNA and RNA nanostructure and exploiting such structures to develop applications in bioimaging, biosensing, diagnostics and therapeutics.

Jean J. Zhao, Ph.D.

Dr. Zhao is Professor of Biological Chemistry and Molecular Pharmacology at the Dana-Farber Cancer Institute where she is a co-leader of the Breast Cancer Program. Her laboratory has integrated mouse genetics with chemical biology to better understand signal transduction pathways in the field of cancer research. Her work on deciphering the role of specific PI 3-kinase isoforms in cancer addresses important basic science questions and has the potential for substantial clinical impact.

As of December 14th, 2016

Karen Adelman, Ph.D.

Dr. Adelman is Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. Her work has revealed that a majority of metazoan gene regulation occurs during early transcription elongation, through controlled pausing of RNA polymerase II. Her recent findings that pause release is a key determinant of gene activity (in response to developmental and environmental factors) has provided new insights into signal-responsive gene expression and its perturbation in cancer cells.
Thomas G. Bernhardt, Ph.D.

Dr. Bernhardt is Professor of Microbiology and Immunobiology at Harvard Medical School. His laboratory combines traditional and modern genetic approaches with biochemistry and cell biology to investigate how bacterial cells grow and divide. Work from his group has provided insight into the fundamental mechanisms underlying these processes and knowledge relevant to targeting them for antibiotic development.

Vincent J. Carey, Ph.D.

Dr. Carey is Professor of Medicine at the Brigham and Women’s Hospital. His research is divided between computational statistics for integrative genomics, and design and analysis of clinical trials in chronic and infectious diseases. His innovative work as co-founder and core developer of “Bioconductor”, a novel open access platform for analysis of genomic data, has had an enormous impact on the work of genomic scientists worldwide.

Mariana C. Castells, M.D., Ph.D.

Dr. Castells is Professor of Medicine at Brigham and Women’s Hospital where she is the Director of the Hypersensitivity and Desensitization Center and the Associate Director of the Mastocytosis Center. Her research is focused on the inhibitory mast cell-dependent processes that lead to cell desensitization, which she has translated into clinical application for thousands of patients with cancer, inflammatory disease and severe infection who need first line therapy. Through desensitization protocols, cancer patients and patients suffering from inflammatory disease and severe infection have been able to increase their quality of life and their life expectancy.

Niteesh K. Choudhry, M.D., Ph.D.

Dr. Choudhry is Professor of Medicine at Brigham and Women’s Hospital where he is Executive Director of the Center for Healthcare Delivery Sciences. His work focuses on design and evaluation of strategies to overcome barriers to the broader use of evidence-based therapies. His research on predictive analytic approaches and strategies to address medication non-adherence, in particular, has been widely adopted by health insurers and provider organizations throughout the U.S. and beyond.
Karen M. Cichowski, Ph.D.

Dr. Cichowski is Professor of Medicine at Brigham and Women’s Hospital and is the Associate Director of Planning and Evaluation for the Dana-Farber Harvard Cancer Center. She is an expert in deconstructing how deregulated signaling pathways drive cancer and uses this insight to discover new targeted therapies. Her work has led to the development of several ongoing clinical trials in currently untreatable Ras-driven cancers.

William C. Faquin, M.D., Ph.D.

Dr. Faquin is Professor of Pathology at Mass General Hospital and Director of Head and Neck Pathology at the Mass Eye and Ear. He is a recognized leader in the field of head and neck cytopathology. His work combining cytomorphology and ancillary markers has contributed to advancements in the detection and diagnosis of thyroid cancer by fine needle aspiration.

Robert C. Flaumenhaft, M.D., Ph.D.

Dr. Flaumenhaft is Professor of Medicine at the Beth Israel Deaconess Medical Center. He is an internationally recognized expert in the area of platelet biology with a focus on platelet granule release and small molecule development in the area of thrombosis. His discovery programs have led to identifying new antithrombotic therapies, one of which is currently in advanced phase clinical trials.

Alexandra J. Golby, M.D.

Dr. Golby is Professor of Neurosurgery at Brigham and Women’s Hospital where she is the Co-Director of the Advanced Multi-modality Image Guided Operating Suite (AMIGO). Her clinical and research interests have focused on developing innovative imaging techniques to define critical brain structures and to guide intraoperative decision making for brain surgery. Her work has contributed to the widespread adoption of functional neuronavigation in the care of patients suffering from brain tumors and other neurosurgical illnesses.
Allan M. Goldstein, M.D.

Dr. Goldstein is Professor of Surgery at Mass General Hospital where he is Chief of Pediatric Surgery and is also Surgeon-in-Chief at MassGeneral Hospital for Children. His clinical and research interests focus on neurointestinal diseases. His work has contributed to our understanding of how the enteric nervous system develops and how neuronal stem cells might be used as a cell-based therapy to treat Hirschsprung disease and other enteric neuropathies.

Annekathryn Goodman, M.D.

Dr. Goodman is Professor of Obstetrics, Gynecology and Reproductive Biology at Mass General Hospital. She has completed training in both pastoral and palliative care and, as a member of the National Trauma and Critical Care Team, she has been deployed to various international disasters including Haiti in 2010 and Nepal in 2015. Recently, she has been consulting in Bangladesh on cervical cancer prevention and the development of medical infrastructure to care for women with gyn cancers.

Timothy T. Hla, Ph.D.

Dr. Hla is Professor of Surgery in the Vascular Biology Program at Boston Children’s Hospital. His research has uncovered novel mechanisms by which lipid mediators such as sphingosine 1-phosphate and prostaglandins act. His work has also described the role of such molecular mechanisms in diseases and has paved the way by which new anti-inflammatory and immunomodulatory drugs are developed.

F. Stephen Hodi, M.D.

Dr. Hodi is Professor of Medicine at the Dana-Farber Cancer Institute. He is a recognized leader in the development of treatments for malignant melanoma and immune therapies for cancer. His work contributed to a new era of immune checkpoint blockade to treat melanoma and other cancers with emphasis in combined approaches.
Matthew H. Kulke, M.D., M.M.Sc.

Dr. Kulke is Professor of Medicine at the Dana-Farber Cancer Institute where he founded and is currently the Director of the Program in Neuroendocrine Tumors at the Brigham and Womens/Dana-Farber. His work has shed light on the molecular characteristics of neuroendocrine tumors. His research has led to the development of multiple new treatments for patients with this condition.

Ursula Matulonis, M.D.

Dr. Matulonis is Professor of Medicine at the Dana-Farber Cancer Institute and is the Medical Director and Disease Center Leader of the Gyn Oncology Program. Her research focuses on developing targeted therapies for gyn cancers, with a specific interest in the genetic changes in ovarian cancer and how that can lead to rationale drug development and selection. She is a recognized leader in the clinical development and testing of PARP inhibitors, and her work has contributed to the regulatory approval of PARP inhibitors to treat recurrent ovarian cancer in the United States and Europe.

Roy H. Perlis, M.D., M.Sc.

Dr. Perlis is Professor of Psychiatry at Mass General Hospital and is the Director of the MGH Center for Quantitative Health. He is a leader in the study of personalized medicine in psychiatric illness, and his laboratory pioneered the use of large-scale electronic health records to drive clinically-relevant risk stratification in psychiatry. His team identified the first genes associated with risk for major depression.

Scott H. Podolsky, M.D.

Dr. Podolsky is Professor of Global Health and Social Medicine at Harvard Medical School and is also the Director of the Center for the History of Medicine at the Countway Medical Library. In addition, he a primary care physician at the MGH. He is a historian of medicine, using social historical methods to frame contemporary medical and scientific concerns such as his monograph on The Antibiotic Era: Reform, Resistance, and the Pursuit of a Rational Therapeutics.
David A. Reardon, M.D.

Dr. Reardon is Professor of Medicine at the Dana-Farber Cancer Institute where he is the Clinical Director of the Center for Neuro-Oncology. His research has focused on the development of novel therapeutic approaches for brain cancer patients. Specifically his work has included a broad array of preclinical mechanistic and efficacy studies in brain cancer models that have rapidly translated to the clinic for the evaluation of multiple novel therapeutic approaches, with a major emphasis on immunomodulatory reagents.

Joan Y. Reede, M.D., M.S., M.P.H., M.B.A.

Dr. Reede is Professor of Medicine at Mass General Hospital and is the inaugural Dean for Diversity and Community Partnership at Harvard Medical School. Her primary focus is workforce, mentoring and leadership development in the biomedical sciences and health policy. She has designed, developed, directed and continues to lead a multi-faceted portfolio of innovative programs that support and shape the career development of faculty, trainees and students at HMS, nationally and internationally.

David P. Ryan, M.D., M.M.S.

Dr. Ryan is Professor of Medicine at Mass General Hospital where he is Chief of Hematology-Oncology and Clinical Director of the MGH Cancer Center. His clinical and research activities have focused on gastrointestinal malignancies where he is a clinical trialist and a recognized leader in the field.

John R. Saltzman, M.D.

Dr. Saltzman is Professor of Medicine at Brigham and Women’s Hospital where he is the Director of Endoscopy and the Advanced Endoscopy Fellowship Program. He is a recognized leader and innovator in advanced endoscopic procedures. His research has led to new approaches to the evaluation, management and therapy of patients with upper GI bleeding.
Navil F. Sethna, M.B.Ch.B.

Dr. Sethna is Professor of Anaesthesia at Boston Children’s Hospital and director of the Mayo Family Pediatric Pain Rehabilitation Center. His clinical and research interests have focused on management of acute and chronic pain disorders in children. He has established a unique specialized interdisciplinary pediatric pain rehabilitation program and his clinical research is focused on studies of quantitative sensory testing in children.

William M. Shih, Ph.D.

Dr. Shih is Professor of Biological Chemistry and Molecular Pharmacology at the Dana-Farber Cancer Institute. His research explores design principles for self-assembling molecular machines, using DNA nanostructures as a model system. He is currently focused on building tools for molecular biophysics and tools for diagnostics and therapeutics.

David K. Simon, M.D., Ph.D.

Dr. Simon is Professor of Neurology at the Beth Israel Deaconess Medical Center, where he is Director of the Parkinson’s Disease & Movement Disorders Center and Chief of the Movement Disorders Division. He conducts laboratory research as well as clinical trials relating to neuroprotection in Parkinson’s disease. His work has advanced our understanding of the role of mitochondrial dysfunction and mitochondrial DNA mutations in Parkinson’s disease.

Lawrence L. Wald, Ph.D.

Dr. Wald is Professor of Radiology at Mass General Hospital where he is the Director of the NMR Core Facility. Dr. Wald is a specialist in MRI instrumentation and acquisition methods. His work has led to new MRI detector arrays and methods to speed up and improve diagnostic imaging with MRI.
Loren Walensky, M.D., Ph.D.

Dr. Walensky is Professor of Pediatrics at the Dana-Farber Cancer Institute and Director of the Harvard/MIT MD-PhD Program. His research focuses on dissecting and targeting the protein interaction mechanisms of the mitochondrial apoptosis pathway, with the goal of developing a new class of cancer therapeutics called “stapled peptides”, one of which is currently undergoing clinical testing. He is also deeply committed to pediatric oncology care and to training the next generation of physicians and scientists.

Benjamin C. Warf, M.D.

Dr. Warf is Professor of Neurosurgery at Boston Children’s Hospital, where he is the Director of Neonatal and Congenital Anomaly/Neurosurgery. He identified neonatal ventriculitis as the chief cause of infant hydrocephalus in East Africa and pioneered a novel endoscopic method for treating infant hydrocephalus that avoids the use of shunts, for which he was awarded a MacArthur Fellowship. He has trained neurosurgeons across North America and throughout the developing world and his current work focuses on hydrocephalus treatment and preventing post-infectious hydrocephalus in sub-Saharan Africa.

Jing Zhou, M.D., Ph.D.

Dr. Zhou is Professor of Medicine at Brigham and Women’s Hospital and is the founding director of the Harvard Center for Polycystic Kidney Disease Research. Her research is focused on answering fundamental research questions related to inherited kidney diseases such as Alport syndrome and Polycystic Kidney Disease. The results of her work have opened new avenues for research relating to kidney diseases, the polycystin protein family, epithelial cell biology and the biology of primary cilia.

Andrew X. Zhu, M.D., Ph.D.

Dr. Zhu is Professor of Medicine at MassGeneral Hospital where he is Director of Liver Cancer Research. He has focused on developing innovative therapies for hepatobiliary cancers, identifying novel molecular markers and genetic mutations, and dissecting the molecular mechanism of drug resistance to targeted therapy. His work has contributed to improving the therapeutic strategies for hepatobiliary cancers.
Peter J. Zimetbaum, M.D.

Dr. Zimetbaum is Professor of Medicine at the Beth Israel Deaconess Medical Center where he is Associate Chief and Director of Clinical Cardiology. His research focuses on the assessment of clinical practice strategies for cardiac arrhythmias. His clinical and administrative responsibilities include developing novel methods for the ambulatory management of patients with cardiovascular disease.